Welcome to our dedicated page for Praxis Precision Medicines news (Ticker: PRAX), a resource for investors and traders seeking the latest updates and insights on Praxis Precision Medicines stock.
Praxis Precision Medicines, Inc. (NASDAQ: PRAX) is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders characterized by neuronal excitation–inhibition imbalance. The PRAX news page on Stock Titan aggregates company announcements, clinical updates, regulatory milestones and capital markets activity related to its precision neuroscience pipeline.
Investors and followers of Praxis can use this page to track developments across the company’s diversified CNS portfolio. News items include progress updates on late-stage product candidates such as ulixacaltamide for essential tremor, vormatrigine for focal onset seizures and generalized epilepsy, relutrigine for developmental and epileptic encephalopathies (DEEs), and elsunersen for early-onset SCN2A-DEE. Praxis frequently reports on Phase 2 and Phase 3 study readouts, FDA interactions such as pre-NDA meetings and Breakthrough Therapy Designations, and changes to registrational trial designs.
The feed also covers corporate and financial disclosures, including underwritten public offerings, at-the-market equity programs, and governance or leadership changes. Form 8-K filings referenced in press releases provide additional detail on clinical data, regulatory feedback and financing terms. Because Praxis emphasizes precision neuroscience and genetic epilepsies, its news often highlights mechanistic data, biomarker findings and functional outcomes in epilepsy and movement disorder studies.
By reviewing this PRAX news stream, readers can follow key catalysts such as NDA preparation, pivotal trial milestones, regulatory designations and capital raises that may influence the company’s trajectory as it advances its CNS portfolio. Bookmark this page to access an organized view of Praxis Precision Medicines’ latest public communications and disclosures.
Praxis Precision Medicines (NASDAQ: PRAX) said the FDA accepted its New Drug Application for ulixacaltamide HCl to treat essential tremor in adults and set a PDUFA target action date of January 29, 2027. No advisory committee meeting is expected.
The NDA is supported by positive Essential3 Phase 3 results and notes a consistent safety profile; ulixacaltamide received Breakthrough Therapy Designation in December 2025.
Praxis (NASDAQ: PRAX) will present expanded Phase 3 Essential3 data for ulixacaltamide at AAN 2026, including a plenary on maintenance of response and topline randomized withdrawal results. Ulixacaltamide has received FDA Breakthrough Therapy Designation; Praxis will present 15 scientific posters and oral sessions April 18–22, 2026.
Praxis Precision Medicines (NASDAQ: PRAX) reported positive topline EMBRAVE Part A results for elsunersen in pediatric SCN2A early-onset developmental and epileptic encephalopathy (DEE). Elsunersen showed a 77% placebo-adjusted seizure reduction from baseline (p=0.015) and sustained benefit in an open-label extension for up to one year.
Additional findings: 57% of patients had a ≥28-day seizure-free period; 100% of treated patients had improvements in sleep, motor function, muscle tone or attention; no drug-related serious adverse events were reported. Nine patients were randomized 3:1; dosing started at 1 mg with escalation to 8 mg.
Praxis Precision Medicines (Nasdaq: PRAX) announced on April 1, 2026 that its Compensation Committee granted restricted stock unit awards covering an aggregate of 3,558 shares to eighteen new non-executive employees under the 2024 Inducement Plan.
The awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4) and vest in four equal annual installments, subject to continued employment on each vesting date.
Praxis Precision Medicines (NASDAQ: PRAX) said the FDA accepted its New Drug Application for relutrigine and granted priority review, assigning a PDUFA target action date of September 27, 2026.
The NDA is supported by the EMBOLD study, which stopped early for efficacy, and relutrigine holds Orphan Drug, Rare Pediatric Disease, and Breakthrough Therapy designations. If approved, relutrigine would be the first FDA-approved therapy for SCN2A and SCN8A developmental and epileptic encephalopathies and eligible for a Pediatric Review Voucher. The EMERALD trial is expected to complete by the end of 2026.
Praxis Precision Medicines (Nasdaq: PRAX) announced on March 4, 2026 that its Compensation Committee granted restricted stock unit awards covering 2,931 shares to fourteen new non-executive employees under the 2024 Inducement Plan.
The awards were granted on March 2, 2026 as inducements under Nasdaq Listing Rule 5635(c)(4) and vest in four equal annual installments, subject to continued employment on each vesting date.
Praxis Precision Medicines (NASDAQ: PRAX) reported Q4 and full-year 2025 results and provided a corporate update. Key developments include two NDA submissions for ulixacaltamide (essential tremor) and relutrigine (SCN2A/SCN8A DEEs), Breakthrough Therapy designations, and multiple 2026 topline readouts.
Financials: $926.1M cash at 12/31/2025, $621.2M net proceeds in Jan 2026, and funding expected into 2028; 2025 net loss $303.3M and R&D $267.1M.
Praxis Precision Medicines (NASDAQ: PRAX) will report fourth quarter and full year 2025 financial results and provide a corporate update before markets open on February 19, 2026 at 8:00 am ET. The company will host a conference call and live webcast; replays will be available on the Events & Presentations page for ~90 days.
Management will present at Guggenheim Biotech Summit on Feb 11, 2026 and TD Cowen Health Care Conference on Mar 2, 2026, with live webcasts and subsequent replays.
Praxis Precision Medicines (Nasdaq: PRAX) announced that on February 2, 2026 the Compensation Committee granted restricted stock unit awards covering an aggregate of 2,964 shares to eight new non-executive employees under the 2024 Inducement Plan.
The awards were granted as inducements under Nasdaq Listing Rule 5635(c)(4) and will vest in four equal annual installments, subject to continued employment on each vesting date.
Praxis Precision Medicines (NASDAQ: PRAX) on Jan 13, 2026 appointed Dr. Orrin Devinsky as Head of Clinical Strategy, a new leadership role reporting to Steven Petrou, Ph.D., President of Research and Development.
Dr. Devinsky brings more than 40 years of clinical experience, > 500 peer-reviewed publications, 16 issued patents, leadership on pivotal cannabidiol trials for rare epilepsies, and prior direction of a major academic epilepsy program. He will guide clinical program architecture, evidence generation, and global medical affairs as Praxis advances a late-stage portfolio toward commercialization.